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Atherosclerosis is a chronic autoimmune inflammatory disease that can cause coronary
artery disease, stroke, peripheral artery disease, depending on which arteries are
affected. At the beginning of atherosclerosis plasma lipoproteins accumulate in the
sub-endothelial space. In response, monocytes migrate from the circulation through
the endothelium into the intima where they differentiate into macrophages. These
early events trigger a complex immune response that eventually involves many cellular
subtypes of both innate and adaptive immunity. The Notch signaling pathway is an
evolutionary conserved cell signaling system that mediates cell-to-cell communication.
Recent studies have revealed that Notch modulate atherosclerosis by controlling
macrophages polarization into M1 or M2 subtypes. Furthermore, it is known that
Notch signaling controls differentiation and activity of T-helper and cytotoxic T-cells in
inflammatory diseases. In this review, we will discuss the role of Notch in modulating
immunity in the context of atherosclerosis and whether targeting Notch may represent a
therapeutic strategy.
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INTRODUCTION
Atherosclerosis is widely recognized as the most common cause of coronary artery disease,
periphery artery disease, and stroke and thus the most relevant player in mortality andmorbidity in
the entire world (http://www.who.int/healthinfo/global_burden_disease/estimates/en). The disease
typically progresses with a slow build-up of lipid-laden plaques in large and medium arteries. It can
remain silent for decades until plaque rupture or erosion leads to the formation of thrombus that
blocks the arterial vessels leading to ischemic injury in the surrounding tissues. Atherosclerosis
is deeply intertwined to chronic inflammation and immune cells are involved in all the stages
of the disease (1). However, only recently, the CANTOS study provided definitive proof that
targeting inflammation improves clinical outcomes in patients with atherosclerosis (2–4). After
the success of the treatment with an anti-IL-1β antibody, efforts to target the immune system
to counteract atherosclerosis are on the rise and potential new strategies to target immunity
and inflammation are being envisioned (5). Notably, very recent data underscored the early
inflammatory component of the disease in the vascular wall, with substantial arterial inflammation
highly prevalent even in middle aged subjects with subclinical manifestations identified through
diagnostic procedures (6, 7).
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The role of Notch pathway in regulating the differentiation
of the different cells of innate and adaptive immune system
cells is well-recognized (8). On the other hand, small molecules
Notch inhibitors and specific antibodies blocking Notch ligands
or receptors have provided greats tool to gain an understanding
of the role of Notch in the immune system under physiological
or pathological conditions (9). The Notch pathway is a major
regulator of cell fate in stem cells, thus in continuously renewing
tissues and its dysregulation has been observed in pathologic
states, including cancer (10). Small molecules inhibiting γ-
secretase (GSI, γ-secretase inhibitors), the enzyme necessary for
the activation of Notch, have been originally developed because
γ-secretase is also involved in a β-amyloid polypeptide, found
in brains of Alzheimer’s disease patients (11). During these past
20 years GSIs with different specificity and modality of action
and other Notch blocking agents have been developed and are
currently being investigated in clinical trials for those cancers
driven by dysregulation of this pathway (12, 13).
In this Review, we will describe the role of Notch in the
modulation of immune responses during the different phases
of atherosclerosis and discuss available evidence suggesting that
the targeting of this pathway may represent a novel therapeutic
strategy for this disease.
THE CORE NOTCH PATHWAY
The Notch pathway is a cell signaling system that mediates
cell-to-cell communication. Notch signaling controls cell fate
choices and modulates crucial cellular functions, such as
cell differentiation proliferation and apoptosis (14). Mammals
express four isoforms of Notch receptors (Notch 1–4), and five
Notch ligands [Delta-like ligand (Dll 1, 3, and 4), and Jagged-1
and 2] (15). Notch receptors are initially synthesized as a single
precursor that migrates to the Golgi apparatus where it is split by
a furin-like protease into an extracellular and a transmembrane
subunit (16). For the assemblage of the functional receptor
the two subunits are transported to the cell-membrane where
they are held together by non-covalent bonds. The binding of
a Notch ligand with its receptor triggers the removal of the
extracellular portion, followed by two subsequent proteolytic
cuts, the first by a disintegrin and metalloprotease (ADAM10
and/or 17) and the second by a γ-secretase, a multiprotein
complex membrane protease, resulting in the release of the
active form intracellular Notch (NICD). In the Notch “canonical”
signaling the NICD migrates into the nucleus where it controls
the transcription of target genes through binding to transcription
factors recombinant binding protein for the immunoglobulin
region κJ (RBPJ) mediating the displacement of co-repressors
and the recruitment of Mastermind proteins (MAML 1–3). The
NICD/RBPJ/MAML complex recruits additional co-activators,
such as p300 and PCAF to guide the transcriptional expression
of the genes under the control of Notch. The best characterized
Notch target genes belong to Hes (Hairy and Enhancer of Split)
and Hey (Hairy and Enhancer of Split with YRPW) families
of transcriptional repressors (17). The Notch signaling can also
function through “non-canonical” pathways: the NICD activity
can be independent of RBPJ; the activation of γ-secretase can
initiate the Notch pathway independently of the binding with
canonical ligand; or Notch signaling is activated in the absence
of the cleavage of the γ-secretase complex (18). Non-canonical
Notch signaling involves interactions with Wnt/β-catenin (19),
mTORC2 (mammalian target of rapamycin complex 2)/Akt (20),
or IKKα/β (18) pathways, and can also occur in mitochondria
where Notch/PINK1 (PTEN-induced kinase 1) complexes
modulate mitochondrial metabolism promoting cell survival by
activating the mTORC2/Akt pathway (21).
THE ONSET OF ATHEROSCLEROSIS
INVOLVES ENDOTHELIAL DYSFUNCTION:
THE ROLE OF NOTCH
At the onset of atherosclerosis plasma lipoproteins accumulate
in the subendothelial space triggering inflammatory responses
that eventually result in the expression of adhesion molecules
and in the impairment of endothelial physiology. Various lines of
evidence have shown that Notch signaling in ECs is dysregulated
by atherogenic stimuli, such as inflammatory cytokines (22–
24), dyslipidemia (25, 26), and disturbed shear stress (27–
29). Conversely, it is well-established that a functional Notch
signaling provides protection from endothelial dysfunction
induced by various atherogenic stressors (23, 24, 29).
Atherosclerotic lesions arise primarily in specific areas of
the arteries, such as bifurcations or curvatures characterized
by a turbulent blood flow and a disturbed shear stress.
In recent times, data supporting a role for Notch as a
transducer of laminar shear stress have been emerging (28).
It has been reported that low shear stress induces the
downregulation of miRNA126-5p resulting in the upregulation
of Dlk1 which, by inhibiting Notch1, hinders ECs proliferation
required for the efficient renewal of the endothelium damaged
by dyslipidemia. Importantly, Mir126(–/–) mice exhibited
exacerbated atherosclerosis (30). In agreement with this study,
a reduced expression of the Notch signaling components was
found in the atheroprone regions of mouse aorta (27). Moreover,
in ApoE-deficient mice the modulation of shear stress with
ivabradine, a heart rate reducing drug, protected the endothelium
in the first phase of atherosclerosis through a mechanism
depending on Notch signaling (31). Molecular mechanisms
underlying the anti-atherogenetic effects of laminar shear stress
through Notch have been recently described by Mack et al.
(29). In this study, the lack of endothelial Notch1 results
in hypercholesterolemia-induced atherosclerotic lesions in the
descending aorta. Additionally, the authors have shown that, in
the endothelium, Notch1 is activated by shear stress and that it is
necessary for themaintenance of junctional integrity. Conversely,
the reduction of Notch1 weakens endothelial junctions and
causes ECs proliferation. A role of Notch in the transduction
of shear stress has also been observed by Polacheck et al. that
demonstrated that shear stress-induced Notch1 activation is
crucial for maintaining the endothelial barrier function. In this
work, findings from experiments in vivo and in an organotypic
model of microvessels that could be perfused at different shear
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stress, revealed that Notch1 controls vascular barrier integrity
through non-canonical signaling: shear stress triggers a Dll4-
dependent proteolytic activation of Notch1 that determines
transmembrane domain (TMD) exposure which is required for
the assembly of the endothelial junction complex (32). Recently,
Miyagawa et al. showed that contacts between ECs and SMCs
are necessary for the activation of Notch1 mediated by BMPR2
(bone morphogenetic protein receptor 2). In ECs, BMPR2 drives
the translocation of p-JNK (phospho-c-Jun N-terminal kinase)
to the cell membrane stabilizing presenilin1 and activating
Notch1. Notch1 promotes ECs proliferation sustaining glucose
metabolism and mitochondrial activity, and it is required for the
integrity of endothelium and for its regeneration following an
injury (33).
An early study in cultured cells by Quillard et al. (34)
showed that TNF-α impairs Notch signaling by altering
Notch4 and Notch2 levels; in turn, the dysregulation of Notch
pathway promotes apoptosis through the downregulation of
the anti-apoptotic protein survivin (23). Interestingly, in the
Quillard studies, the Notch alteration was linked with an
induction of the VCAM-1 and ICAM-1 adhesion molecules. The
discovery that Notch signaling downregulates the expression of
adhesion molecules was subsequently confirmed and extended
by Briot et al. which demonstrated that Notch signaling in the
endothelium is curbed by various pro-atherogenic stimuli and
that Notch1 is essential to impede the expression of inflammatory
molecules and the binding of monocytes (25). In this study
Notch1 was found down-regulated in aortic ECs in response to
a high-fat diet or to exposure to pro-atherogenic oxidized lipids
or inflammatory mediators TNF-α and interleukin-1β (IL-1β).
Decreased Notch1 signaling promoted inflammatory cell binding
to ECs and increased expression of pro-inflammatory molecules
IL-8 and CXCL1. Of note, Notch antagonized inflammatory
phenotype when the protein was ectopically overexpressed in ECs
exposed to stressors that cause Notch suppression (25).
Emerging evidence shows that Notch signaling mediates
communication between EC and immune cells after endothelial
activation induced by atherogenic stress factors. Pabois et al.
have shown that TNF-α drives the endothelial expression of
Dll4 which, in turn, promotes the polarization of macrophages
to a pro-inflammatory phenotype that induces IL-6 production
(35). Moreover, it was recently found that, in mice, endothelial
Dll1 drives the Notch2 dependent conversion of Ly6C(hi)
(inflammatory) monocytes into Ly6C(lo) (patrolling) monocytes
(36). Furthermore, Krishnasamy et al. have recently reported that
macrophage maturation is controlled by Dll1 expressed in ECs
and requires the canonical signaling of RBPJ in macrophages,
which simultaneously suppresses an inflammatory polarization
of macrophages. Conversely, mice lacking Dll1 or RBPJ showed
an accumulation of inflammatory macrophages resulting in
compromised tissue repair and arteriogenesis (37). Interplay
between ECs and macrophages has been also shown in vitro co-
cultures: specifically sprouting angiogenesis is enhanced in co-
culture of ECs with M1 polarized macrophages, but not with M2
activated macrophages, and this effect is dependent on Notch
signaling (38).
NOTCH REGULATES
MACROPHAGES-MEDIATED
INFLAMMATION IN ATHEROSCLEROSIS
AND ISCHEMIC HEART DISEASE
In the early stages of atherosclerosis circulating monocytes
bind to ECs expressing adhesion proteins and migrate to
the intima where they differentiate into macrophages. During
the progression of atherosclerosis, monocytes attracted by
inflammatory cytokines continue to infiltrate the growing plaque
contributing to perpetuate the inflammation. Macrophages are
classically divided into a high-inflammatory M1 subset and
an anti-inflammatory (or less-inflammatory) M2 subset. M1
macrophages are classically defined as pro-inflammatory players
secreting cytokines, such as IL-1, IL-6, IL-12, IL-15, IL-18,
MIF, TNF-α able to trigger T cell-mediated responses. M2
macrophages hold anti-inflammatory activities able to resolve
plaque inflammation and release different cytokines (IL-4,
IL-10, and IL-13) from M1 (39). TGF-β produced by M2
macrophages has a role in the biology of the vascular wall by
influencing cell proliferation, differentiation, and production of
extracellular matrix (40). Overall, inflammatory macrophages
(M1) sustain mechanisms that favor atherosclerosis progression,
whereas M2 macrophages drive mechanisms that are able to
suppress plaque formation and progression and even to support
plaque regression (39). Interestingly, the number of M1 and
M2 macrophages changes depends on the plaque field. For
example, M1 macrophages are abundant in regions that are
inclined to rupture. On the contrary, M2 macrophages are more
abundant in areas where thicker fibrous caps and smaller areas
of necrosis are present, demonstrating the plaque–stabilizing
function of macrophages (41, 42). A comprehensive discussion
of macrophages’ role can be found in recent reviews (5, 39).
Studies on cultured monocytes found that Notch1 induces
M1 macrophage differentiation and heightens inflammatory
responses by increasing IL-6, MCP-1, and TNF-α production.
Conversely, Notch1 inhibition drives in the direction of an
increase of M2 differentiation promoting the secretion of anti-
inflammatory cytokines IL-10 and IL-1RA (43, 44). Aoyama
et al. have shown that in ApoE−/− mice, the treatment with
Notch inhibitor DAPT reduced macrophages migratory activity
and repressed ICAM-1 expression in macrophages that led to
decreased macrophage infiltration in the atherosclerotic plaques
(45). The first direct evidence of Notch involvement in regulating
functions of human macrophages in atherosclerosis stems from
a study by Fung et al. in which the authors observed the
expression of Dll4 and Notch3 in infiltrating macrophages and
atherosclerotic plaques. In this study, in vitro experiments with
pro-inflammatory molecules, such as LPS, IL-1β, or modified
LDL have been shown to promote the expression of Dll4 in
macrophages. Dll4, in turn, causes additional pro-inflammatory
responses in a manner dependent on Notch receptors thereby
triggering a positive feedback loop in plaque macrophages
(46). Pabois et al. have shown that, during microvascular
inflammation, there is an increase in the expression of Dll4
in both ECs and macrophages, suggesting that Dll4 may be
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a marker of endothelial activation and could play a role in
endothelial/macrophage interactions during inflammation (35).
Recently, the same group demonstrated that Dll4 is the ligand
involved in the Notch-dependent selection process promoting
the differentiation of M1 macrophages and preventing the
differentiation of M2 macrophages blocking the expression of
M2 genes induced by IL-4. Noteworthy, Dll4 was also able to
promote the induction of apoptosis selectively in M2 cells (47).
Consistent with a pro-inflammatory role of Notch signaling,
Fukuda et al. have been shown in LDLr−/− mice that high-
fat/high-cholesterol diet promotes expression of Dll4 in the
atherosclerotic plaques and in fat tissue. Inhibition of the
Notch signaling with anti-Dll4 antibody reduced atherosclerotic
lesions, diminished plaque calcification while improving insulin
resistance, and decreasing fat accumulation. These changes were
associated with a reduction of macrophage accumulation and
decreased MCP-1 levels. In vitro experiments revealed that
Dll4-mediated Notch signaling increases MCP-1 expression by
activating NF-κB. Noteworthy, also in this setting Dll4 induced
macrophages M1 polarization (48). Nakano et al. reported that
in a mice model of chronic kidney disease (CKD) accumulation
of the uremic toxin 3-indoxylsulfate drives the expression of Dll4
in macrophages with consequent Notch signaling-induced pro-
inflammatory responses. In this model an anti-Dll4 antibody was
able to lessen both macrophage accumulation and atherosclerosis
(49). More recently, it has been shown that the inhibition of
Furin, an enzyme involved in Notch1 activation (16), reduces
atherosclerosis progression in LDLr−/− mice. Of note, mice
treated with furin inhibitors also had reduced inflammation and
less macrophages in the plaque (50).
Molecular details of the function of Notch in activated
macrophages have been investigated in cultured cells. In
vitro experiments found that Notch1 activation occurs in
response to LPS or IFN-γ and is implicated in macrophage
activation by upregulating the expression of ICAM-1 and major
histocompatibility class II antigens (MHCII) in macrophages
(51). In addition, it has been shown that Notch1 positively
regulates IL-6 production via NF-κB in activated macrophage
(52). Following binding to its receptor, IL-6 activates STAT3
that, in turn, induces Dll1 expression that initiates the Notch
signaling. Notch increases NF-κB activation that results in IL-6
production which transduces stabilization of STAT3 activation
establishing a positive feedback loop (53). Notch-RBPJ signaling
regulates the transcription factor IRF8 to promote inflammatory
macrophage polarization and expression of prototypical M1
effector molecules, such as IL-12 and iNOS (54). Conversely,
blockade of canonical Notch signaling was shown to decrease
macrophage-mediated inflammation correlating with improved
late wound healing in diabetes (55). Recently, the role of
Notch in regulating M1/M2 polarization was confirmed by
Huang et al., that found that miR-148-3p is expressed following
activation of Notch1 and promotes M1 polarization while
inhibiting M2 differentiation (56). Furthermore, it has been
reported that in ApoE−/− mice the anti-atherosclerotic miR-
181b modulates macrophage polarization by directly targeting
Notch1 (57). Importantly, Xu et al. showed that Notch1
induces an increase of mitochondrial glucose oxidation that
in turn triggers the expression of M1 pro-inflammatory
genes (58).
Apparently in contrast with previous studies, Fondi et al. have
shown that Notch is involved in polarization ofM2macrophages.
In this study, it was seen that mice deficient in RBPJ in
myeloid cells poorly differentiate into M2 (59). In addition,
Onishi et al. have shown that Dll1 inhibits GM-CSF-dependent
differentiation of monocytes into mature macrophages but
promotes differentiation of dendritic cells (DCs) progenitors
and further differentiation into mature DCs in the presence of
GM-CSF, IL-4, and TNF-α (60).
It is well-established that M1 macrophages infiltration worsen
ischemic damage after myocardial infarction (MI) hindering the
resolution of inflammation and scar formation; by contrast, the
presence of anti-inflammatory M2 macrophages in the infarct
area facilitate pro-reparative processes (61). Yin et al. have shown
in a rat model that after MI, M1 macrophages that infiltrate the
infarct area express high levels of Notch1. The administration
of the Notch inhibitor DAPT 30min prior to MI caused a
decrease of total macrophages in the infarct area, but enhanced
the ratio of M2-activated macrophages. Furthermore, rats pre-
treated with DAPT had a decrease in the cardiac re-innervation
after MI, this eventually resulted in a better recovery of heart
electric functionality after MI (62). The expression of the C-C
chemokine receptor type 2 (CCR2) in macrophages is controlled
by RPBJ (63). Recently, Bajpai et al., found that, following MI,
tissue resident CCR2+ macrophages promote the recruitment
of inflammatory monocytes to the injured heart. These
monocytes secrete pro-inflammatory cytokines contributing to
the adverse cardiac remodeling. On the contrary, resident CCR2-
macrophages inhibit pro-inflammatory leukocyte recruitment
protecting from adverse remodeling after MI (64, 65).
Overall, these findings indicate that Notch signaling in
monocytes and vascular macrophages promotes inflammation by
facilitating a pro-inflammatory M1 phenotype at the expense of
the anti-inflammatory M2 subtype. In this process, the axis Dll1-
Dll4/Notch1 plays a crucial role both by initiating M1 program
and inhibiting M2 differentiation.
FUNCTIONAL PHENOTYPES OF T-CELLS
DETERMINE ATHEROSCLEROSIS
PROGRESSION: A POSSIBLE ROLE OF
NOTCH
In T cells activation, the MHC molecules interact with oxLDL,
microbial antigens, and heat shock proteins (HSP 60), which help
to protect cells from stress damage driven by stressed endothelial
cells. Furthermore, engagement of the co-stimulatory molecule
CD28 to T cells allows interactions with CD80 or CD86 on
antigen-presenting cells (APCs). As for monocytes/macrophages,
T cell functional phenotypes can be modified by environmental
factors and different “pabulum,” thus modulating their possibility
to act as regulatory or inflammatory cells.
The importance of Notch signaling in T cells has been
established in diseases of autoimmune and inflammatory
origin, but studies directly addressing the role of Notch
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in atherosclerosis are lacking. In this section, we will
describe how Notch regulates the functionality of T cells in
immune/inflammatory diseases and the putative role of Notch in
modulating adaptive cells in the progression of atherosclerosis.
Notch in T-Helper Cells
Most of the T cells present in human plaques are CD4 T-
helper (Th) cells and different T-helper cell subgroups arise
following micro-environment cues and following encounter with
APCs. Th1 cells secrete IFN-γ, IL-2, IL3, and TNF-α and have
been shown to be the main subtype in human atherosclerotic
plaques and the pro-atherosclerotic effect of these cells have been
shown in several animal studies (1). IFN-γ is a pro-atherogenic
cytokine and growth inhibitor of SMCs and ECs that also
affects macrophage polarization. After arterial damage, growth
of SMCs is inhibited by IFN-γ secreted from Th1 cells, which
determines atherosclerotic plaque destabilization and rupture.
Furthermore, IFN-γ increases TNF-α and IL-1 production,
which are strong pro-inflammatory molecules and indirectly
inhibit the proliferation of SMCs and endothelial cells (66).
The capacity of Notch ligands Dll1/Dll4 to promote Th1
cell differentiation is supported by many in vitro and in vivo
studies in which Notch inhibition was achieved by different
approaches. Maekawa et al. have shown in cultured T cell that
soluble Dll1 induces T-cells differentiation into IFN-γ secreting
Th1 phenotype (67). In DCs/T-cells co-culture it has been shown
that Dll4-deficient DCs have limited capacity to induce CD4
T-cell activation, proliferation, and cytokines secretion (68).
In mice, treatment with γ-secretase inhibitors reduced disease
progression in a Th1 cell-mediated experimental autoimmune
encephalomyelitis (EAE) (69) while the deletion of Dll4 from
DCs resulted in a reduced ability to mount a CD4-dependent
response in mice (68). Furthermore, Riella et al. have shown that
Dll1 blockade results in a Th1 decrease in an allograft model (70).
Interestingly, anti-Dll4 antibodies diminished T-cells secretion
of IFN-γ and TNF-α (71) suggesting that Delta-ligands can not
only affect differentiation but also regulate cytokines secretion
in differentiated Th1 cells. Studies in transgenic mice unable to
activate RBPJ because of dominant-negative MAML expression,
showed that canonical Notch signaling is not involved in
Th1 polarization (72), and similarly, in T-cells lacking RBPJ
expression, the capacity to drive a Th1 cells in response to
infection was maintained (73). Dongre et al. confirmed that
differentiation to Th1 cells occurs independently from RBPJ and
demonstrated that Notch signaling triggers Th1 polarization by
non-canonical signaling involving Notch1-dependent activation
of NFκB pathway (74).
Th17 cells are characterized by the expression of RORγt
and the production of IL-17 which have been linked to the
atherosclerosis (75). Under the effect of inflammatory cytokines,
Th17 cells can be switched from barrier-protective IL-10
secreting T-effector cells (T-eff) into pathogenic drivers that
produce IL-22, and IFN-γ (76). IL-1, IL-6, and IL-23 drive this
Th17 switch into pathogenic effector cells. Of note, dual IL-
17/IFN-γ-producing Th17 cells are present in atherosclerotic
human coronary arteries at a higher frequency than in the general
circulation (77). In the last decade, accumulating evidence has
highlighted the role of Notch in regulating differentiation and
functionality of the Th17 subset. It is well-established that, in
EAE, Th17 cells arise from naïve T-cells in the central nervous
system where, along with Th1, promote autoimmunity (78). In
this context, it has been shown that Notch inhibition, by γ-
secretase inhibitors (69, 71) or by antibodies against Dll1 (79),
results in a decrease of Th1 and Th17 cells. Noteworthy, DCs
expressing high levels of Dll4 have greater ability than other DCs
to promote the generation of Th1 and Th17 from naïve T-cells
(80, 81). Conversely, blocking Dll4 with antibodies decreased
Notch signaling in T cells stimulated with Dll4 expressing DCs,
thus reducing Th1 and Th17 cells (82). Administration of DAPT
repressed Th1- and Th17-mediated responses in spleen and
lymph nodes resulting in a decrease of circulating IFN-γ and IL-
17 in a mouse model of arthritis (83). Meyer Zu Horste et al.
have shown in transgenic mice that RBPJ deletion in T-cells did
not impair Th17 differentiation induced by TGF-β1 and IL-6.
Nevertheless, in the same study, it was seen that RBPJ determines
the pathogenicity of Th17 cells by regulating IL-23R and IL-10
expression (84). These findings indicate that canonical Notch
signaling may modulate differentiation and cytokines secretion.
Contrary to the effect observed for Delta-like- ligands, Jagged-1
suppressed Th17 cell differentiation induced by IL-6 and TGF-
β (85). Recently, Zaman et al. found that DCs lacking RBPJ
promote the generation of Th17 cells but have limited capacity in
instructing CD4 cells to differentiate into Tregs in the presence of
TFG-β, thus suggesting that Notch signaling in DCs has a crucial
role in determining balance between Th17/Tregs (86).
Th9 cells are characterized by production of IL-9, their
development occurs from naive CD4T cells in the presence of
IL4 and TGF-β (87). Some evidence suggests that IL-9 producing
Th9 cells help the development of atherosclerosis (88). Elyaman
et al. have reported that Jagged2, but not Dll1, induces Th9 cell
polarization. Moreover, CD4T cells lacking Notch1 and Notch2
display a reduced capacity to differentiate into Th9 when exposed
to IL-4 and TGF-β (89).
Th2 cells are present in atherosclerotic plaques at lower
frequency compared to Th1 cells. Initially, Th2 cells have been
thought to act as anti-atherosclerotic by opposing Th1 phenotype
(90) but subsequent studies lack clear demonstration of the
atheroprotective role of Th2 cells. Engelbertsen (91) et al.
reported that subjects with a high ratio of circulating Th2 cells
has a lower cardiovascular disease risk, but triggering a Th2
response did not exert an anti-atherosclerotic effect in ApoE−/−
mice. Zhao et al. found that IL-4 (the main driver of Th2
differentiation) protects against atherosclerosis by promotingM2
over M1 macrophage inflammatory phenotype (92). By contrast,
IL-4 delivery was not able to decrease atherosclerosis in murine
models of atherosclerosis (93, 94).
Different lines of evidence have shown that canonical Notch
signaling instructs for Th2-type response. CD4T cells lacking
RBPJ retain limited capacity to differentiate into IL-4 producing
Th2-type while cells CD4T cells deficient for Notch-1 andNotch-
2 completely lose the capacity to mount a Th2-type response
(95). RBPJ binding sites presence on IL-4 gene enhancers regions
suggests a direct role of Notch in IL-4 transcription in Th2
cells and possibly in other IL-4-secreting cells (95, 96). The
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capacity of Notch to control Th2 cell differentiation has been
shown in many experimental models in vivo (96, 97). The
production of specific cytokines in Th2 cells is under control
of the transcription factor Gata3 (98). Notch1 and RBPJ both
bind in the proximity of Gata3 promoter and the activity of
this complex is required for the Notch-dependent production
of IL-4, indicating that Notch controls Th2 cells differentiation
and IL-4 production by directly promoting Gata3 expression
(97, 99). In mice, expression of Jagged2 in DCs promotes Th2
cells polarization and IL-4 production by activating Notch1
canonical signaling (100). Tindemans et al. have shown in a
murine model of asthma that RPJB in T-cells is necessary for the
induction of a Th2-mediated allergic inflammation but, in this
model, Jagged1 or Jagged2 deletion on DCs did not affect the
capacity to promote a Th2 immune response (101). This may
indicate that Notch signaling could be activated to induce Th2
cells also through ligands-independent pathways. Interestingly,
Damle et al. found that mice with DCs lacking ADAM10 are
unable to produce the cytokines necessary for Th2 differentiation
but maintain the ability to drive Th1 and Th17 immunity (102).
In this study, the reactivation of Notch signaling with N1ICD
overexpression rescued DCs capacity to induce a Th2 response
(102). This suggests that, in DCs, not only Notch ligands, but
also Notch receptors, play a role in instructing Th-cells toward
Th2 phenotype.
Regulatory T cells (Tregs) are a subpopulation of CD4 T-
helper cells that modulate immunity. Regulatory T-cells hinder
the differentiation of CD4 T-cells into effector subtypes and
modulate APCs activity by producing modulatory cytokines,
such as IL-10, IL-35, and TGF-β. It has been convincingly shown
that Tregs have a protective role in atherosclerosis (103, 104).
Human atherosclerosis is linked with low circulating Tregs (105),
Tregs are also detectable in atherosclerotic plaques (106) where
their number positively correlates with plaque stability (107).
On the contrary, lower numbers of Tregs are correlated with
a heightened infiltration of pro-inflammatory leukocytes into
the plaque (108). Tregs depletion in ApoE−/−mice increased
atherosclerotic lesions and plaque instability (109, 110). Several
studies, in vitro and in animal models of inflammatory diseases,
found that Notch signaling increases Tregs population (111).
Notch-induced Tregs have been shown to decrease severe
allergic airway inflammation (112, 113) to prolong allograft
survival (114), and to alleviate the progression of autoimmune
diabetes (115, 116).
Importantly, atherosclerotic and hypercholesterolemic
microenvironments drive Tregs cell plasticity.
CD4+CCR5+IFN-γ+FoxP3+T-bet+ cells (referred to as
Th1-Tregs) are derived from Tregs and their presence is
increased in atherosclerotic lesions of ApoE−/− mice (117).
Noteworthy, Th1-Treg cells display deficient regulatory
functions in vitro and impaired expression of genes linked
to Treg cells immunosuppressive activity (117). Up to 40%
of the CD4T cells in atherosclerotic aorta of ApoE−/− mice
showed a CCR5+FoxP3+T-bet+ phenotype and secreted
relevant levels of IFN-γ and TNF-α (118). These cells, named
FoxP3+CCR5+CD25− Teff cells by the investigators, trigger
atherosclerosis in adoptive-transfer experiments and do not
suppress Teff cell growth. In already established Tregs, the
deletion of RPJB or Notch1 increases the ability of Tregs to
suppress Th1 responses, while the ectopic expression of Notch1
in Tregs causes an increase in Th1 activity (119). Similarly, in
Tregs isolated from a mice model of autoimmune uveitis, it
has been shown that Jagged1 and Dll1 downregulates Foxp3
expression limiting the immunosuppressive activity of Tregs.
Conversely, antibodies against Jagged1 and Dll1 rescued Foxp3
levels. Importantly, transplantation of Tregs with Notch1
deficiency resulted in an increase in the release of inflammatory
cytokines and in cellular infiltration in the uveitic eyes (120).
In summary, findings indicate that Notch sustains
Tregs differentiation from progenitors, by contrast, in
differentiated Tregs, Notch promotes a switch toward a
pro-inflammatory phenotype.
Notch in CD8 Cytotoxic T Cells
CD8 cytotoxic T cells are activated following the binding of their
T-cell receptor (TCR) to the major histocompatibility complex
(MHC) expressed on APCs. CD8 cells cytotoxic activity is related
to the secretion of the effector proteins perforin, granulysins, and
granzymes that trigger apoptosis of target cells by forming pores
on their membranes (121). In addition, CD8T cells produce
TNF-α and IFN-γ that locally potentiate cytotoxic effect further
fuelling inflammation (122). CD8 cytotoxic T cells are present
in human atherosclerotic lesions, as proven decades ago (123),
and their number is linked with atherosclerosis pathophysiology
(124). In the plaque, CD8T cells exacerbate inflammation,
and exert cytotoxic activity toward lesion-stabilizing cells, such
as smooth muscle cells and ECs, driving the atherosclerosis
progression and plaque instability (125). By contrast, it must be
noted that CD8 T-cell subsets with immunomodulatory capacity
which limit atherosclerosis are also present in the plaque (125).
An early study by Wong et al. has found that Dll1 binding
to splenic CD8T cells results in a strong decrease of IFN-γ
production with a concomitant increase of IL-10 production
(126). The involvement of Notch pathway was also observed
in peripheral CD8T cells in which it was shown that Notch
is necessary for TCR-mediated activation and that Notch
inhibition blocks IFN-γ production (127). Furthermore, it has
been reported that inhibition of Notch signaling in CD8T cells
blocks the production of TNF-α and cytotoxic effector molecules
perforin and granzyme B (128, 129). Noteworthy, Maekawa et al.
have shown that DCs expressing high levels of Dll1, trigger
in CD8T cells a higher production of cytotoxic molecules. In
the same study, authors observed that Notch2-deficient T cells
poorly differentiate into cytotoxic CD8T cells (130). Activated
CD8T cells can differentiate into terminal effector cell (TEC)
or can become memory precursor cell (MPC). In CD8T cells,
the concomitant Notch1 and Notch2 deficiency, or the lack of
RBPJ, reduced TEC differentiation resulting in defects in host
defense and eradication of tumors (131). Taken together these
results suggest that Notch activates CD8T cells at different levels.
Notch signaling in CD8T cells promotes the cytotoxic activity of
the effector cells, in addition Notch instructs CD8T cells toward
TEC differentiation.
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NOTCH MODULATION OF THE
CROSSTALK BETWEEN INNATE AND
ACQUIRED IMMUNITY MAY CONTROL
ATHEROSCLEROSIS PROGRESSION
DCs constitute a bridge between the innate and the adaptive
immunity and the role of Notch signaling as mediator of
communication between DCs and T-cells has been extensively
investigated (132). As previously described, DCs express Notch
ligands Dll1, Dll4, Jagged-1, Jagged-2, while T-cells express Notch
receptors. The Notch ligand-receptor associations in DCs/Th
initiate the differentiation program toward a specific T cell
functional phenotype (95). For instance, it has been shown that
DCs expressing Dll1 or Dll4 promote the differentiation toward
pro-atherosclerotic Th1 (68, 69, 82). On the contrary, Jagged
ligands instruct T cells toward the less inflammatory Th2 and Th9
subtype (132).
Myeloid-derived suppressor cells (MDSCs) constitute a
heterogeneous population of immature myeloid cells that
originate in the bone marrow during inflammatory diseases
and migrate to inflamed tissue where they strongly suppress
T-cell responses in autoimmunity (133). Recently, the murine
MDSCs subset CD11b+Gr1+ has been found to possess anti-
atherosclerotic activity in LDLr−/− mice as MDSC adoptive
transfer in these animals decreased the number and activity of
Th1 and Th17 cells in the plaque and reduced the atherosclerotic
lesions (134). Acute coronary syndrome (ACS) patients displayed
expansion of MDSC population identified as CD14+HLA-DR-
/low that when isolated from ACS patients MDSCs were found
to contrast T-cell proliferation and IFN-γ production in vitro
more efficiently compared to MDSC isolated from healthy or
stable angina subjects (135). Transgenic mice overexpressing
ADAM10, an enzyme involved in the activation of Notch,
displayed a systemic expansion of CD11b+Gr1+ MDSCs (136).
Conversely, blockage of Jagged1 and Jagged2 in MDSCs have
been shown to inhibit T-cell repression activity of these cells
(137). In light of these findings, the role of Notch in modulating
the interactions between innate and adaptive immunity, may
be also relevant in the progression of atherosclerosis as already
seen in cancer (138). However, it must be noted that the role of
Notch signaling inMDSCs has beenmainly studied in the context
of cancer and there is still a lot to be understood about these
cells. For a comprehensive and critical discussion of the role of
Notch in MDSCs we refer the reader to the following references
(111, 138, 139).
CONCLUSIVE REMARKS AND CLINICAL
PERSPECTIVES
Atherosclerosis is a chronic inflammatory disease driven by a
complex interplay between vascular and immune cells, with an
involvement of the Notch signaling pathway in each phase of
the disease. Activation of Notch promotes atherosclerosis by
inducing a pro-inflammatory M1 phenotype in macrophages
FIGURE 1 | Inflammatory stimulus triggers M1 polarization via Notch. Inflammatory stimulus, such as IL-1β, TNF-α, oxLDL upregulates Dll4 on endothelial cells (or
APCs). Binding between endothelial Dll4 (and possibly Dll1) and Notch1 or Notch3 in macrophages initiates Notch program that results in macrophages M1
polarization and concomitant inhibition of M2 differentiation. M1 activated macrophages feed inflammation and atherosclerosis by secreting further inflammatory
cytokines, Notch blocks M2 polarization inhibiting M2 capacity to resolve inflammation/lesion.
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at the expense of the M2 anti-inflammatory subtype. Even
if the detailed molecular mechanisms are still not completely
known, solid evidence has shown that the Dll4/Notch1 axis
is pivotal in favoring M1 polarization, while blocking M2
immunosuppressivemacrophages and their cytokines (Figure 1).
T cells in atherosclerotic plaques can either promote–or protect
from–the onset and progression of atherosclerosis. Notch
ligands Dll1, Dll4, Jagged1, Jagged2 on APCS interact with
Notch receptors on T-cells and this interaction regulate their
differentiation. APCs expressing Dll1 or Dll4 promote the
differentiation toward pro-atherosclerotic Th1 whereas Jagged
ligands instruct T cells toward the less inflammatory Th2 subtype.
Jagged also mediates the inhibitory activity of MDSCs on CD4
and CD8 T-cells (137). Notch signaling is also necessary for
Tregs differentiation from naïve T cells, however, in already
established Tregs Notch mediates the differentiation toward a
Th1-like inflammatory phenotype (111). Although clear evidence
demonstrates both the involvement of T cells in atherosclerosis
and of Notch signaling in T cell regulation, the specific role
played by the Notch signaling in T cells in the context of
atherosclerosis has not been directly investigated. Based on the
findings discussed in this review, it appears likely that Notch
may favor atherosclerosis by promoting Th and CD8 cells
formation (Figure 2). Consequently, inhibition of the Notch
pathway could be a novel strategy to counteract inflammation
of the vascular wall, and thus atherosclerosis, by interfering with
the production of cytokines fromM1macrophages and with Th1
cells infiltration in the plaque. In principle, this strategy could
have the advantage of increasing the immunomodulatory activity
of M2 macrophages without depleting anti-inflammatory Tregs
in the plaque.
Notch inhibition for cancer and other indications has been so
far mainly relying on GSIs. GSIs are a heterogeneous group of
small molecules that prevent Notch cleavage by the γ-secretase
enzymatic complex, thus reducing the levels of active Notch
FIGURE 2 | Notch may regulate T helper cells fate in the plaque. Dll1 and Dll4
ligands expressed in APCs promote Th1, Th9, and Th17 differentiation while
suppressing Th2 differentiation. Jagged1 induces Th2 differentiation. Dll1 and
Jagged1 both suppress Tregs activity.
(140). GSIs were developed based on their activity on Notch1
but can also inhibit, depending on the cell type, the cleavage of
other Notch paralogs or interfere with other pathways (11, 13).
Currently, there are several GSIs being investigated in Phase
I and/or II clinical trials in cancer patients (clinicaltrials.gov).
Specific drug administration approaches are required to limit
their main toxic effect which is intestinal toxicity (141). Studies
in vivo have shown that GSIs are able to interfere with the
progression of atherosclerosis. Systemic administration of GSI
(LY411,575 0.2, and 1.0 mg/kg/day for 8-weeks) suppressed
Notch signaling in ApoE-deficient mice fed a high fat diet and
reduced total plaque areas in the aortic sinus, plus macrophages
from these mice showed reduced levels of ICAM-1 andmigration
ability. 0.2 mg/kg/day did not cause loss weight and alterations
of intestine and thymus whereas with the 1 mg/kg/day dose
intestinal and immunologic toxicity was observed, suggesting
that only low doses of GSI could be used long term without
adverse effects (45). Based on these results, GSI treatment in
patients with atherosclerosis could dampen the inflammatory
activities of macrophages; the overall effects on atherosclerosis
progression would depend on how the treatment affects the
complex interplay between acquired and innate immunity,
and thus, the balance between pro- or anti-atherosclerotic T
cells. For precise targeting of macrophages, mesoporous silica
nanoparticles containing GSIs could be used to specifically
deliver these molecules to these cells (142). Alternatively, cell-
specific delivery to macrophages of Notch inhibitors miRNAs
(143) using siRNA loaded exosomes could be another specific
approach to block Notch and inflammation in these cells
(49, 144). GSIs-coated stents could be used to prevent re-
occlusion in some patients, after percutaneous intervention, since
Notch could be also involved in restenosis due to its effect on
promotion of vascular smooth muscle cells proliferation (145).
Of interest, a recent study has shown that sulindac, a non-
steroidal anti-inflammatory drug, interferes with triple negative
breast cancer growth by inhibiting Notch in cancer stem cells
without inhibiting Notch expression or cleavage in murine T cells
(146). Based on these findings, it would be of interest to test the
effect of this drug in the context of atherosclerosis, specifically in
the regulation of Notch signaling in macrophages.
A clear understanding of the role played by each receptor
and/or ligand in each cell of the innate and acquired immune
system involved in atherosclerosis could lead to a more precise
targeting of the Notch signaling by antibody–mediated blocking
of a specific component of the pathway. Blocking antibodies
against Dll4, Notch1, Notch2, or Notch3 are already being
tested in phase I clinical trials in cancer patients (9). An anti-
Dll4 antibody has been employed to successfully interfere with
vascular inflammation and atherosclerosis progression in a mice
model of atherosclerosis (48). Our data in peripheral artery
disease (PAD) patients showing that intraplaque levels of Dll4
mRNA could be associated with the progression of the disease
suggest that PAD patients could also benefit of this approach
(147). Given the widespread expression of Dll4 in the vasculature
and the immune system, concerns about toxicity of the treatment
have been addressed. Long term administration (12 weeks) of
agents blocking Dll4 in mice caused no toxicity in one study
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(48) whereas Yam et al. reported adverse effects in the liver
(148). In cancer patients, administration of anti-Dll4 antibody
caused heart failure in a subset of patients (149). Differently from
Dll4, in the context of atherosclerosis Jagged1-mediated signaling
could be protective, since anti-Jagged1 immunotherapy has been
shown to inhibit MDSCs and overcome tumor-induced tolerance
by activating T-cell (137). Consistently, high levels of Jagged1
mRNA intraplaque were associated to a less inflamed plaque
profile and a slower progression of disease in PAD patients (147).
Clinical trials employing Tregs are ongoing in organ
transplantation, type I diabetes, and graft vs. host disease.
These trials mainly used naturally occurring FoxP3+Tregs from
patients, followed by in vitro expansion and reinfusion. Of note,
adoptive transfer of Tregs inmicemodels reduced atherosclerosis
considerably, suggesting that a similar strategy may be beneficial
in patients (150). On light of this, targeting of Notch pathway
could be utilized to improve the generation and specificity
of T-cells for adoptive transplant immunotherapies as already
proposed for cancer-immunotherapy (151).
As discussed in previous paragraphs, the first step of
atherosclerosis involves the interplay between the endothelium
and infiltrating immune cells, step in which Notch1 in particular
plays a crucial role by preventing the expression of adhesion
molecules on ECs. Strategies aimed to prevent a reduction of
Notch1 caused by turbulent shear stress (31) or dyslipidemia
(25) or low estrogen conditions, as in post-menopausal women
or breast cancer patients treated with anti-estrogens (152) could
reduce endothelial dysfunction and therefore, plaque formation
in atheroprone areas of the aortic endothelium. Heart rate
reducing drugs (31), miRNA (30), or specific estrogen receptor
agonist (24) could be used to prevent Notch1 downregulation in
these areas.
The CANTOS study provided definitive prove that tackling
inflammation by blocking IL-1β with the monoclonal
antibody canakinumab can be a successful strategy to
reduce atherosclerosis progression (2). It should be noted
that canakinumab efficacy depends on the reduction of
inflammation achieved. Individuals with hsCRP concentrations
<2 mg/L experienced a 25% reduction in cardiovascular
events compared to a non-significant 5% reduction in those
with on-treatment hsCRP levels ≥2 mg/L (153). Similarly,
blocking IL-6 by a specific antibody has shown a protective
effect in atherosclerosis even though the results of this treatment
are still unclear (5). Targeting Notch in immune cells could
represent a novel approach to counteract inflammation and
thus atherosclerosis. To this aim a deeper knowledge of the
specific roles of each Notch receptor and ligand in innate
and adaptive immune cells, in the context of atherosclerosis,
is needed.
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